|Clinical Trial ID||NCT03735979|
|Lead Sponsor||University of Cincinnati|
The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with 0.9mg/kg IV rt-PA within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.
|Acute Ischemic Stroke||Drug: Argatroban, Drug: Eptifibatide, Drug: Placebo||Phase 3|
|Age||Gender||Accepts Healthy Volunteers|
|18 Years and older.||All||No|